xene-8k_20180315.htm

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 15, 2018

 

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Canada

001-36687

98-0661854

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

200-3650 Gilmore Way

Burnaby, British Columbia, Canada

 

V5G 4W8

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (604) 484-3300

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 


 

 

Item 8.01

Other Events

On March 15, 2018, Xenon Pharmaceuticals Inc. (the “Company”) announced the meeting, record date and certain other information relating to its 2018 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval (“SEDAR”) in Canada.

A copy of the filing submitted to SEDAR is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit Number

Description

99.1

SEDAR filing submitted March 15, 2018.

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Xenon Pharmaceuticals Inc.

 

 

 

 

Date:  March 15, 2018

 

By:

/s/ Ian Mortimer

 

 

 

Ian Mortimer

 

 

 

President & Chief Financial Officer

 

 

xene-ex991_6.htm

Exhibit 99.1

 

Craig Colosso

Relationship Manager

 

American Stock Transfer & Trust Company, LLC

Charlotte, North Carolina

 

Tel: 718.921.8337

Email: ccolosso@amstock.com

www.amstock.com

 

 

 

 

 

March 15, 2018

 

 

 

Alberta Securities Commission

 

 

British Columbia Securities Commission

 

 

Ontario Securities Commission

 

 

 

 

RE:  Xenon Pharmaceuticals Inc.

 

Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders:

 

Date of meeting:

June 4, 2018

Record date for notice:

April 9, 2018

Record date for voting:

April 9, 2018

Beneficial ownership determination date:

April 9, 2018

Securities entitled to notice:

Common Shares

Securities entitled to vote:

Common Shares

Issuer mailing directly to non objecting beneficial owners:

No

Issuer will pay for objecting beneficial owner material distribution:

Yes

Issuer using notice-and-access for registered investors:

No

Issuer using notice-and-access for non-registered investors:

No

Notice-and-access stratification criteria:

N/A

 

 

Yours very truly,

 

/s/ Craig Colosso

 

Craig Colosso

Relationship Manager